In the third quarter, several major funds reshaped their positions in Eli Lilly. Ascent Group increased its holding by 3.3%, acquiring an additional 575 shares to reach 17,821 shares worth $13.6 million. Generate Investment Management surged its stake by 23.1%, adding 15,352 shares and bringing its total to 81,813 shares valued at $62.4 million, making the company its seventh-largest position. Conversely, Calamos Advisors trimmed its position by 1.5%, selling 4,255 shares and ending the quarter with 274,313 shares valued at $209.3 million. Diversified Trust raised its exposure by 16.4%, purchasing 2,758 shares to hold 19,592 shares worth $14.9 million. Overall, institutional and hedge fund ownership remains high at 82.5%.

In the third quarter, the company reported earnings per share of $7.02, beating consensus estimates by $0.60, on revenue of $17.6 billion versus expectations of $16.09 billion. Net margin stood at 30.99% and return on equity reached 109.5%. Management reaffirmed full-year guidance of $23.00–23.70 in adjusted EPS. The board also declared a quarterly dividend of $1.73 per share, up from $1.50, yielding approximately 0.6% and reflecting a payout ratio of 29.35%. With a current ratio of 1.55 and debt-to-equity of 1.71, the company maintains a balanced financial position while returning capital to shareholders.

Eighteen analysts currently recommend either a buy or stronger rating, including four labeled as Strong Buy, with five holding a neutral stance. Consensus target price across the broker community stands near $1,155. Key upward revisions include Wells Fargo raising its target to $1,200 and BMO Capital Markets also setting a $1,200 objective. Loop Capital remains more conservative at $950, while Truist increased its forecast to $1,182. These ratings reflect confidence in the company's ability to sustain growth through its robust pipeline and strong profitability metrics.